Hormonal secretion and quality of life in Nelson´s syndrome and Cushing´s Disease after long-acting repeatable Octreotide. A short series and update.

ARREGGER AL, CARDOSO EML, SANDOVAL OB, TUMILASCI EGM, SANCHEZ R, CONTRERAS LN

AMERICAN JOURNAL OF THERAPEUTICS

LIPPINCOTT WILLIAMS & WILKINS

Lugar: Philadelphia; Año: 2012 p. 1 - 5

1075-2765

Clinical management of persistent ACTH excess in Nelson´s syndrome (NS) and Cushing´s disease (CD) remains a challenge. Somatostatin (SS) and its analogs as octreotide decrease ACTH secretion through SS receptors (sst) of pituitary cells. To our knowledge there are no reports on the effect of long-acting repeatable octreotide (oct-lar) on hormonal secretion and quality of life in patients with NS and CD who failed conventional therapy. Herein we describe the effects of treatment with oct-lar (20 mg/ i.m. month) in one woman with NS and two women with persistent CD . Oct-lar therapy reduced ACTH secretion and improved quality of life in NS, by contrast in CD it failed to control ACTH and cortisol secretion and quality of life remained unchanged.